clinical trial · NCT04252742
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
Amgen·phase4·completed·n = 512
MigraineErenumabPlacebo
brief summary
The primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.
started
Sep 15, 2020
primary completion
Oct 26, 2023
completion
Oct 26, 2023
last updated
Mar 31, 2026
official title
Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Phase 4 Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol